Pro members get same-minute coverage on the stocks they track. Free plans update twice a day.
Get ProCounts of positive, neutral, and negative news items. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Showing 7 stories from July 2026
Show allThe items moving the net sentiment the most, by direction and influence.
Cipla Profit Dips in FY26 as Pharma Sector Faces Headwinds
Direct news · Medium influence · Long term
Nifty Pharma Index Falls Nearly 2% on Trump Tariff Plan for Generic Drugs
Direct news · Medium influence · Long term
Cipla Posts Record FY26 Revenue of Rs 28,000 Crore on Broad-Based Growth
Direct news · Medium influence · Short term
Cipla FY26 Revenue Crosses Rs 28,000 Crore, Announces Rs 13 Dividend
Direct news · Medium influence · Short term
Macro, commodity, FX and regulatory forces that moved CIPLA in this range, with the stories behind each.
Also monitored for CIPLA (no news in this range): US FDA / USFDA.
Sign up free to track CIPLA, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track CIPLA for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Cipla Stock: US Arm Gets One USFDA Observation at New York Facility
How news sentiment on Cipla Ltd. (CIPLA) has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
